Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Duchenne muscular dystrophy Stories

2012-10-01 22:20:49

Rare Disease Industry Leaders and Advocates Honored; Recording Artists Chris Mann, Katrina Parker and Elliott Yamin Gave Touching Performances DANA POINT, Calif., Oct. 2, 2012 /PRNewswire-USNewswire/ -- On September 27, 2012, rare disease patients, advocates, patient organizations, government agencies, pharmaceutical companies, medical researchers, celebrities, Olympic champions and private sector representatives attended the Global Genes | R.A.R.E. Project (www.globalgenes.org) 1(st)...

2012-09-27 06:29:05

University of Alberta Professor to be Given Grant to Continue Potentially Groundbreaking Work in Duchenne Muscular Dystrophy HACKENSACK, N.J., Sept. 27, 2012 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD) announced today that it will award the University of Alberta's Toshifumi Yokota, Ph.D. a $50,000 grant to continue his work in exon skipping as a potential therapy for Duchenne muscular dystrophy. Dr. Yokota is the Assistant Professor and Research Chair in...

2012-09-19 02:25:06

WACO, Texas, Sept. 19, 2012 /PRNewswire-USNewswire/ -- For the fifth year in a row, college football coaches nationwide will join together in support of the Coach To Cure MD program, which will be held during games of Saturday, September 29, 2012. The rapidly growing annual effort has raised more than a million dollars to battle Duchenne muscular dystrophy. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO ) On September 29th, American Football Coaches Association (AFCA) members...

2012-09-17 06:28:41

Dongsheng Duan, Ph.D. to be Given Grant to Continue Work With SERCA2a in Duchenne Muscular Dystrophy HACKENSACK, N.J., Sept. 17, 2012 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD) announced today that it will award the University of Missouri's Dongsheng Duan, Ph.D. a $280,000 grant to continue his work to treat cardiomyopathy in Duchenne muscular dystrophy through a gene therapy approach. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO) Dr. Duan...

2012-09-10 02:29:55

CAMBRIDGE, Mass., Sept. 10, 2012 /PRNewswire/ -- DART Therapeutics, LLC, an innovative, new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), announced today the appointment of its executive team. Co-Founder and Executive Chairman Eugene W. Williams transitions to a full-time role as CEO, and Ernest D. Bush Ph.D. joins as Chief Scientific Officer. DART also adds Dr. Elliot Goldstein as Chief Medical Officer and Cabot Brown as Chief Financial...

2012-08-02 02:30:33

TUCSON, Ariz., and PLEASANTON, Calif., Aug. 2, 2012 /PRNewswire-USNewswire/ -- Safeway Inc. kicked off its annual fundraising campaign for the Muscular Dystrophy Association August 1 to support health care services for those living with neuromuscular diseases and global MDA research initiatives. (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO) (Logo: http://photos.prnewswire.com/prnh/20120730/DC49109LOGO) The nationwide campaign runs through September 3, giving customers...

2012-08-02 07:03:06

(Ivanhoe Newswire) - Duchenne muscular dystrophy affects 1 in every 3,600 male infants each year. Due to the way the disease is inherited, girls are not affected. Muscular dystrophy consists of a group of inherited disorders causing muscle weakness and loss of muscle tissue, which progressively becomes worse. Researchers seem to have discovered a promising new way to reverse the symptoms of the disease in mice. Scientists have reversed symptoms of myotonic muscular dystrophy in mice by...

2012-07-09 10:54:16

The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies. A group of untreatable...

2012-06-27 02:27:17

SOUTH PLAINFIELD, N.J., June 27, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the initiation of an open-label study in the European Union, Israel, Australia and Canada for patients with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who received ataluren in a prior, PTC-sponsored clinical study. The primary objective of this study is to gain further information on the long-term safety and tolerability of ataluren, an investigational new drug. PTC launched a...

2012-06-26 02:28:52

CINCINNATI, June 26, 2012 /PRNewswire-USNewswire/ -- The first landmark randomized clinical trial for a cardiac drug regimen in Duchenne muscular dystrophy (DMD) is testing whether earlier treatment can stop or slow down heart damage that usually kills people with the disease. (Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO) The study is a collaboration of Cincinnati Children's Hospital Medical Center, Ohio State University (OSU) and The Christ Hospital in Cincinnati....